My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Psychemedics Corp. (PMD)
NASDAQ:PMD
PMD nasdaq
United States
Psychemedics

Psychemedics Stock Analysis & Ratings

Psychemedics Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Psychemedics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

PMD

PMD Stock Stats

Previous Close$8.21
Open$8.21
Bid8 x 8000
Ask10.33 x 400
Today’s Range$8.05 - $8.33
52-Week Range$3.58 - $8.60
Volume9.85K
Average Volume22.89K
Market Cap$45.78M
Beta0.71
P/E Ratio-30.4
EPS-0.27
Earnings DateNov 15, 2021
Ex-Dividend DateFeb 20, 2020

Company Description

Psychemedics Corp.

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.
Sector
Healthcare
Industry
Medical Diagnostics & Research
CEO
Raymond C. Kubacki
Employees
138
ISIN
US7443752057
Address
289 Great Road, Acton, MA, 01720, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

PMD FAQ

What was Psychemedics’s price range in the past 12 months?
Psychemedics lowest stock price was $3.58 and its highest was $8.60 in the past 12 months.
    What is Psychemedics’s market cap?
    Psychemedics’s market cap is $45.78M.
      What is Psychemedics’s price target?
      Currently, no data Available
      What do analysts say about Psychemedics?
      Not enough analysts have published a price target to provide an average price target.
      When is Psychemedics’s upcoming earnings report date?
      Psychemedics’s upcoming earnings report date is Nov 15, 2021 which is in 19 days.
        How were Psychemedics’s earnings last quarter?
        Psychemedics released its earnings results on Aug 10, 2021. The company reported $0.024 earnings per share for the quarter, beating the consensus estimate of N/A by $0.024.
          Is Psychemedics overvalued?
          According to Wall Street analysts Psychemedics’s price is currently Overvalued.
            Does Psychemedics pay dividends?
            Psychemedics pays a Quarterly dividend of $0.18 which represents an annual dividend yield of 10.97%. Psychemedics’s last Quarterly dividend payment was on Mar 03, 2020. Psychemedics’s upcoming ex-dividend date is Feb 20, 2020
              What is Psychemedics’s EPS estimate?
              Psychemedics’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Psychemedics have?
              Psychemedics has 5,540,000 shares outstanding.
                What happened to Psychemedics’s price movement after its last earnings report?
                Psychemedics reported an EPS of $0.024 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.589%.
                  Which hedge fund is a major shareholder of Psychemedics?
                  Among the largest hedge funds holding Psychemedics’s share is Royce & Associates LLC. It holds Psychemedics’s shares valued at N/A.

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis